drugset / Trial / NCT06510374
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Timeline
- Start
- 2024-10-01
- Primary completion
- 2028-06-30
- Completion
- 2031-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nadofaragene Firadenovec | Unknown | — | Other |